Adamas Pharma Cmn (ADMS) 13.67 $ADMS Allergan and Adamas

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Adamas Pharma Cmn (ADMS) 13.67 $ADMS

Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC® Patent Litigation
PR Newswire - Wed Aug 31, 7:00AM CDT
Allergan plc (NYSE: AGN) a leading global pharmaceutical company, today announced that its subsidiaries Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd. and Allergan USA, along with Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), have entered into a settlement agreement with Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC.
AGN: 234.54 (-2.45), ADMS: 13.67 (+0.68)

Adamas Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the second quarter of 2016.
ADMS: 13.67 (+0.68)

Adamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Wed Jun 22, 5:00AM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced additional data from its Phase 3 clinical program of ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease (PD) at the 20 Annual International Congress of Parkinson's and Movement Disorders in Berlin, Germany. Data was presented from two trials -- EASE LID and EASE LID 2 -- by Rajesh Pahwa, M.D., a recognized expert in PD and LID. Levodopa-induced dyskinesia, which is a condition characterized by involuntary movements without purpose, can become severely disabling, rendering people with Parkinson's disease unable to perform routine daily tasks.
ADMS: 13.67 (+0.68)

Adamas Announces Positive Results from its Phase 2 Proof-of-Concept Study of ADS-5102 for the Treatment of Walking Impairment in Multiple Sclerosis (MS) Patients
GlobeNewswire - Mon Jun 13, 7:00AM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive findings from its Phase 2 proof-of-concept study designed to evaluate ADS-5102 (amantadine HCl) extended-release capsules in individuals with multiple sclerosis (MS) who have impaired walking. Data from the study suggest that ADS-5102 is well tolerated in the MS patient population and has a significant positive impact on walking speed. The company plans to present these data at an upcoming scientific conference.
ADMS: 13.67 (+0.68)

Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 20th International Congress of Parkinson's and Movement Disorders
GlobeNewswire - Mon May 16, 5:00PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that data from EASE LID and EASE LID 2, trials from the company's Phase 3 clinical program of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease, will be highlighted in two poster presentations at the 20 Annual International Congress of Parkinson's and Movement Disorders, being held June 19 to 23, 2016, in Berlin, Germany.
ADMS: 13.67 (+0.68)

Adamas reports 1Q loss
Automated Insights - Tue May 10, 5:01PM CDT
EMERYVILLE, Calif. (AP) _ Adamas Pharmaceuticals Inc. (ADMS) on Tuesday reported a loss of $13.8 million in its first quarter.
ADMS: 13.67 (+0.68)

Adamas Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 10, 4:07PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the first quarter of 2016.
ADMS: 13.67 (+0.68)

Adamas Announces New Employment Inducement Grant
GlobeNewswire - Fri May 06, 4:41PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) Adamas today announced that its new General Counsel and Corporate Secretary, Jennifer Rhodes, received a grant of an option to purchase 67,500 shares of the company's common stock, at a per share exercise price of $14.70, the closing trading price on May 6, 2016, and 11,250 restricted stock units, pursuant to the terms of her employment agreement with Adamas. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
ADMS: 13.67 (+0.68)

Adamas Announces Positive Top-line Results from its Phase 3 EASE LID 3 Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients with Parkinson's Disease
GlobeNewswire - Thu Apr 28, 6:04AM CDT
Third Randomized Clinical Trial Meets Primary and Key Secondary Endpoints
ADMS: 13.67 (+0.68)

Adamas to Host Conference Call and Webcast to Provide Company Update
GlobeNewswire - Wed Apr 27, 7:09PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will host a conference call and webcast on Thursday, April 28, at 8:00 a.m. ET/ 5:00 a.m. PT, to provide a company update.
ADMS: 13.67 (+0.68)

Adamas Presents Positive Findings From the Phase 3 EASE LID Clinical Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) Associated with Parkinson's Disease at the American Academy of Neurology Annual Meeting
GlobeNewswire - Tue Apr 19, 7:45PM CDT
Anti-dyskinetic Effect Consistent Across Primary and Secondary Outcome Measures
ADMS: 13.67 (+0.68)

Adamas Announces Data Update at the 68th American Academy of Neurology Annual Meeting
GlobeNewswire - Thu Apr 14, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Rajesh Pahwa, M.D., Laverne & Joyce Rider Professor of Neurology, Director of the Parkinson's Disease and Movement Disorder Center at the University of Kansas Medical Center, will present emerging science abstract # 014, "ADS-5102 (amantadine HCl) Extended-Release Capsules Reduced Levodopa-Induced Dyskinesia in the Phase 3 EASE LID Study," on Tuesday, April 19, from 5:45 p.m. to 7:15 p.m. PT at the 68 American Academy of Neurology Annual Meeting, being held April 15 to April 21, 2016, in Vancouver, British Columbia.
ADMS: 13.67 (+0.68)

Adamas Pharmaceuticals Provides Review of 2015 and Projected Future Milestones
GlobeNewswire - Tue Jan 12, 3:05PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today is providing a summary of 2015 corporate highlights and planned future milestones. Adamas, which is developing new medicines for chronic neurological disorders, utilizes its technology platform to improve the pharmacokinetics profiles of approved drugs, alone and in fixed-dose combinations. The company is developing ADS-5102 for two indications: levodopa-induced dyskinesia (LID), a complication associated with the treatment of Parkinson's disease, and major symptoms associated with multiple sclerosis (MS) in patients with walking impairment. Adamas also has ADS-4101 in preclinical development for epilepsy (partial onset seizures). In addition, the company has a partnership with Allergan for two approved products, Namzaric(TM) and Namenda XR, which are marketed in the U.S. by Allergan.
AGN: 234.54 (-2.45), ADMS: 13.67 (+0.68)

Adamas Pharmaceuticals (ADMS) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 8:13AM CST
As of late, it has definitely been a great time to be an investor in Adamas Pharmaceuticals Inc (ADMS)
ADMS: 13.67 (+0.68)

Adamas prices public offering at USD23.00 per share
M2 - Thu Jan 07, 3:16AM CST
Biopharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) said on Wednesday that it has priced a public offering of 2,500,000 shares of its common stock.
ADMS: 13.67 (+0.68)

Adamas Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Jan 06, 9:08PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the pricing of its underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $23.00 per share. Adamas also granted the underwriters a 30-day option to acquire an additional 375,000 shares from Adamas. The offering is expected to close on January 12, 2016, subject to customary closing conditions.
ADMS: 13.67 (+0.68)

Adamas plans public offering of 2.5m common shares
M2 - Wed Jan 06, 4:23AM CST
Biopharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) said on Tuesday that it intends to issue 2,500,000 shares of its common stock in a public offering.
ADMS: 13.67 (+0.68)

Adamas Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jan 05, 6:15AM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it plans to offer 2,500,000 shares of its common stock in an underwritten public offering. Adamas expects to grant the underwriters a 30-day option to acquire an additional 375,000 shares. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ADMS: 13.67 (+0.68)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 135

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 20

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 78

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 29

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 194

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 117

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 59

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating the Rising Tide of AI-Driven Cyber Threats

Updated Category News Views 118

The Evolving Landscape of Cyber Threats In today's world, artificial intelligence is rapidly changing the nature of cyber threats. Recent studies reveal that a significant number of companies have encountered AI-driven cyberattacks, highlighting a critical gap in their defense strategies. Despite this alarming trend, many organizations are yet to fully embrace AI in their...

Continue Reading
Insight into the Bullish Movements Surrounding DPZ Stock

Updated Category News Views 58

Understanding the Options Dynamics for Domino's Pizza Investors are expressing a clear bullish sentiment towards Domino's Pizza as evident from the recent options market activities. Analyzing the options history for Domino's Pizza (DPZ), we found a total of 10 significant trades. These trades reveal that approximately 50% of traders leaned towards bullish strategies while...

Continue Reading
PDD Holdings Faces Legal Challenges Over Securities Violations

Updated Category News Views 230

PDD Holdings Faces Legal Challenges Over Securities Violations PDD Holdings, Inc. is currently facing a major class action lawsuit. This legal action stems from accusations that the company misled investors about potential compromises to its applications, raising serious concerns about user privacy, particularly regarding unauthorized access to private messages. Details...

Continue Reading
Significant Shareholder Announcement for Kenmare Resources

Updated Category News Views 98

Major Holdings Notification for Kenmare Resources Plc Understanding the dynamics of major shareholdings is essential for investors and stakeholders alike. Kenmare Resources Plc has recently updated the market regarding key holdings that affect its share structure. The notification process is transparent, with clear communication ensuring that all relevant details are...

Continue Reading
Exploring High-Yield Dividend Stocks for Income Investors

Updated Category News Views 65

Dive into Dividend Investing Dividend investing is often overlooked, especially in an era dominated by the latest advancements in technology and artificial intelligence. While the allure of tech growth may be tempting, savvy investors understand the enduring value of reliable income-generating stocks. The world of dividend stocks is vast, and their potential for...

Continue Reading